Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc. (XRTX) news covers a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and related disorders driven by aberrant purine metabolism and elevated uric acid. Company updates emphasize programs that target xanthine oxidase, a key enzyme in uric acid production, and explore how genetic and molecular insights can inform treatment strategies.
Readers of this page can follow announcements on XORTX’s lead XRx-026 gout program and its proprietary oxypurinol formulation XORLO™, including regulatory interactions, Investigational New Drug (IND) preparation, clinical trial plans, and progress toward potential New Drug Application (NDA) submissions. News also highlights development of XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney and organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy.
In addition to clinical and scientific milestones, XRTX news items report on financing activities such as registered direct offerings, at-the-market issuances, and private placements, as well as Nasdaq listing updates, including minimum bid price deficiency notices and compliance timelines. Corporate developments, including board changes, strategic planning, and the planned acquisition of the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited, are also covered.
This news feed brings together scientific findings on xanthine oxidase and uric acid, regulatory and clinical progress in gout and kidney disease programs, and capital markets disclosures. Investors and observers can use it to monitor how XORTX’s research, pipeline evolution, and financing decisions shape the company’s efforts in gout and kidney-related therapeutics.
XORTX (NASDAQ: XRTX) confirmed a 1-for-5 share consolidation will take effect on April 6, 2026. According to the company, the consolidation received required approvals from the TSX Venture Exchange and Nasdaq.
The move replaces every five old common shares with one new common share and will adjust the company’s issued and outstanding share count on the effective date.
XORTX (NASDAQ: XRTX) announced results of its annual and special meeting held March 24, 2026. Approximately 2,407,148 common shares were represented, about 35% of outstanding shares. All matters presented were approved, including election of five directors, auditor appointment, reapproval of the stock option plan, and approval of a share consolidation.
Detailed voting results are available in the Report of Voting Results filed on the company’s SEDAR+ profile.
XORTX (NASDAQ: XRTX) announced a change to the effective date of its previously disclosed share consolidation from March 27, 2026 to April 6, 2026. The consolidation remains a 1-for-5 share consolidation and is still subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The company attributed the change to timing considerations and confirmed the consolidation will only proceed after receipt of all required exchange approvals.
XORTX (NASDAQ: XRTX) approved a one-for-five share consolidation effective March 27, 2026, reducing issued and outstanding common shares from 6,962,218 to approximately 1,392,444, subject to rounding. The action is intended to satisfy Nasdaq’s $1.00 continual listing requirement and a 10-day price condition by April 13, 2026.
No name change will occur. Fractional post-consolidation shares will be cancelled if under one-half or rounded up if one-half or greater; no cash will be paid for fractions. Convertible securities will be proportionately adjusted. Trading will resume under XRTX with new CUSIP 98420Q405.
XORTX (NASDAQ: XRTX) announced that shareholders approved a share consolidation at the March 24, 2026 annual meeting, authorizing up to a 5-for-1 consolidation to be completed within one year.
The move aims to meet NASDAQ’s continued listing requirement that shares trade above $1.00 (including a 10-day condition by April 13, 2026). Prior to consolidation there are 6,962,218 issued common shares; post-consolidation outstanding shares are approximately 1,392,443, subject to fractional rounding rules. The Consolidation remains subject to TSXV approval and will begin trading post-consolidation on a date set with the TSXV.
XORTX (NASDAQ: XRTX) announced three substitute director nominees — George Scorsis, Richard Grieve and Mika Grasso — to be proposed at its Annual and Special Meeting on March 24, 2026. The appointment is a condition of a significant financing currently under negotiation and subject to TSXV approval; if financing fails, the nominees will resign and vacancies will be filled later. Proxies in favour of management will be voted for the New Nominees unless shareholders instruct otherwise. Shareholders were mailed meeting materials on March 2, 2026 and the proxy deadline is March 20, 2026. Voting assistance is available through Laurel Hill Advisory Group.
XORTX (NASDAQ: XRTX) filed and mailed its Meeting Materials for the Annual and Special Meeting of shareholders. The mailing occurred on March 2, 2026, registration record date is Feb 20, 2026, proxy deadline is March 20, 2026 at 10:00 a.m. Calgary Time, and the Meeting is set for March 24, 2026.
Shareholders will vote to elect five directors, appoint the auditor, approve the stock option plan, and consider an articles amendment to consolidate common shares up to five (5) pre-consolidation for one (1) post-consolidation. The Board unanimously recommends voting FOR all items.
XORTX (NASDAQ: XRTX) said it amended its October 17, 2025 term sheet with Vectus to extend the deadline to close the acquisition of the renal anti-fibrotic program, including the novel chemical entity VB4-P5, to on or before March 31, 2026.
The acquisition remains subject to finalized closing documents, regulatory approvals, stock exchange requirements and applicable securities laws. XORTX also scheduled its Annual and Special Meeting for March 24, 2026 (record date Feb 20, 2026) and granted 20,000 stock options at CAD 0.69 for five years to new director Krysta Davies Foss.
XORTX (NASDAQ: XRTX) highlights peer-reviewed research linking 410 genetic factors (including 149 new) to gout-related inflammatory pathways and to increased xanthine oxidase (XO) expression, supporting XO inhibition as a therapeutic approach. The company cites supporting human and animal studies tying higher XO expression to hyperuricemia, kidney dysfunction, diabetes, sepsis/ARDS and polycystic kidney disease.
Corporate updates: appointment of Krysta Davies Foss to the board; three directors resigned reducing the board to five. XORTX corrected the October 29, 2025 financing numbers and confirmed the US$1.1M registered direct offering closed with a 7% cash commission. Acquisition of a renal anti-fibrotic program from Vectus remains pending ASX approval with closing targeted by Jan 13, 2026.
XORTX (NASDAQ: XRTX) closed a registered direct offering on Oct 29, 2025 raising gross proceeds of US$1,102,500 by issuing 1,750,000 securities at US$0.63 each (572,470 common shares and 1,117,530 pre-funded warrants).
Each pre-funded warrant is exercisable for one common share at $0.001. The company intends to use net proceeds for working capital and general corporate purposes. D. Boral Capital acted as sole placement agent and will receive 87,500 agent warrants exercisable at US$0.69 beginning 181 days after issuance for 18 months.
Shares/warrants were issued under an effective Form F-3 shelf registration (File No. 333-269429).